Aerie Pharmaceuticals Announces Potential Breakthroughs with New Preclinical Research

ByConnor Hodde

Aerie Pharmaceuticals, Inc. (AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today potentially breakthrough findings from new preclinical research.  The research found that RhopressaTM suppressed the activity of profibrotic proteins – TGF-beta 2 and CTGF – on human trabecular meshwork cells in an in vitro model.  In addition to RhopressaTM’s potential anti-fibrotic activity, another recent Aerie preclinical study indicates that RhopressaTM may increase the perfusion of the trabecular meshwork with aqueous humor.

Read the entire article here

Similar Posts

FDA approves first retinal implant for rare eye disease

ByConnor Hodde

The U.S. Food and Drug Administration has approved the first artificial retina, an implanted device that replicates some of the function of the retina, helping to restore vision to people blinded with a rare genetic disorder. The device is intended to replace the function of light-sensing cells in the retina destroyed by retinitis pigmentosa, an…

Avalanche Biotechnologies Closes Transaction With Annapurna Therapeutics

ByConnor Hodde

Avalanche Biotechnologies, Inc. (AAVL) today announced the closing of the previously announced transaction with Annapurna Therapeutics.  “The new management team is focused on applying our extensive clinical development expertise to advance the company’s gene therapy programs into the clinic.  We intend on dosing our first patients for A1AT deficiency by the end of this year…

Once-daily CsA-MiDROPS™ are superior to other CsA drops dosed twice-daily

ByConnor Hodde

Ophthalmic distribution studies indicate significantly increased drug concentration with CsA-MiDROPS (Cyclosporine A microemulsion) compared with Restasis. CsA-MiDROPS is well tolerated with little toxicity in a 2-week tolerability study. In the DED model, both 0.05% and 0.1% CsA-MiDROPS conferred a significant effect and were more effective than Restasis for treating experimental DED when dosed twice per…

Serum retinol-binding protein-induced endothelial inflammation is mediated through the activation of toll-like receptor 4

ByConnor Hodde

“Retinol-binding protein 4 (RBP4) is a novel adipokine (adipose-derived cytokine) that is clinically associated with obesity, insulin resistance, type 2 diabetes (T2DM), and cardiovascular disease. In addition, patients with proliferative diabetic retinopathy (DR) have increased serum RBP4 levels compared to diabetic patients with mild or no retinopathy, which raises the possibility that RBP4 is somehow…

Cell transplant restores sight in mice

ByConnor Hodde

Experimental cell transplants can improve the sight of visually impaired mice, it has been widely reported. The Independent called the research behind the news a “major step towards cure for blindness”, while The Guardian said the work is “the first demonstration that cell transplants can restore useful vision”. During the research, scientists used mice bred…

Diabetic Retinopathy, Microalbuminuria Predict GFR Decline

ByConnor Hodde

Having diabetic retinopathy and/or microalbuminuria predicted a much higher rate of annual decline in glomerular filtration rate (GFR) in a new study of patients with type 2 diabetes living in Japan. Diabetic retinopathy is a known risk factor for microalbuminuria, and microalbuminuria is a risk factor for macroalbuminuria, but to date it has been unclear…